Probing the Markers of Disease to Diagnose and Treat
C2N is pioneering novel, intelligent ways to develop drugs against brain disorders at a more rapid pace and lower cost than conventional methods. In addition, we are commercializing point-of-care diagnostics to enable early detection of conditions like Alzheimer’s disease (AD). We are firm believers that early detection of disease will prove essential for effective disease modification.
Our Flagship Product
C2N offers a number of SILK™ and SISAQ™ platforms for measuring specific proteins in both CSF and plasma. For the stable isotope labeling kinetic (SILK™) platform, we infuse a stable, non-radioactive isotope labeled amino acid into human subjects. In C2N’s flagship product, the SILK-Aβ® assay, 13C6 leucine is used, since it is an essential amino acid and readily crosses the blood brain barrier. The stable isotope incorporates into newly synthesized proteins in the brain, which we sample through serial collection of various biological fluids.